Autoimmune Hemolytic Anemia (AIHA) : Becca Greenstein and Rebekah Wood Immunology 2 December 2014
Autoimmune Hemolytic Anemia (AIHA) : Becca Greenstein and Rebekah Wood Immunology 2 December 2014
Autoimmune Hemolytic Anemia (AIHA) : Becca Greenstein and Rebekah Wood Immunology 2 December 2014
Autoimmune Hemolytic
Anemia (AIHA)
Becca Greenstein and Rebekah Wood
Immunology
2 December 2014
What is AIHA?
Increased destruction of erythrocytes due to the
presence of anti-erythrocyte autoantibodies (AEA)
Decreased life span
Multiple types
Primary, Secondary, Warm, Cold, Mixed, and Drug
induced
1
11/24/2014
Symptoms
Onset typically slow
Referable to anemia
In secondary AIHA,
symptoms of primary
illness may overshadow
Jaundice
Splenomegaly ~20%
Erythrophagocytosis
http://www.medvet.umontreal.ca/clinpath/banq-im/cytology/erythophagieE.htm
Figure 1 Hematological Diseases
2
11/24/2014
Epidemiology
Annual incidence is approximately 1-3 cases per
100,000 people
No known predisposition
AIHA Subtypes
Classification based on optimal RBC-autoantibody
reactivity temperatures
3
11/24/2014
wAIHA Continued
Binding of self AB (Polyclonal) to Rh proteins, causing
Fc receptors to mediate removal of RBCs within the
spleen
4
11/24/2014
wAIHA Mechanism
5
11/24/2014
cAIHA Mechanism
6
11/24/2014
Diagnosis
Recognition of hemolysis and anemia
Jaundice and abnormally dark urine
Diagnosis
http://emedicine.medscape.com/article/1731264-overview
7
11/24/2014
Treatments
Based on type of antibody involved (IgG, IgM, or IgA)
and whether primary or secondary
Treatments Continued
Immunotherapy the treatment of disease by inducing,
enhancing, or suppressing an immune response
Classified as suppression immunotherapy if the
immunotherapy reduces or suppresses the immune
response
Corticosteroids or Rituximab
Rituximab is a humanized monoclonal antibody directed
against CD20 on pre-B cells and mature B lymphocytes
8
11/24/2014
Future Treatments
More efficacious and less toxic
Soluble receptors, monoclonal antibodies, and molecular
mimetics
Study Questions
1. Describe Autoimmune Hemolytic Anemia and the mechanism for
the warm subtype.
9
11/24/2014
Study Questions
3. Which is not a treatment or potential treatment for AIHA?
a. The treatment of the disease using the drug Rituximab, which contains
humanized monoclonal antibody directed against CD20 on pre-B cells
and mature B lymphocytes and results in apoptosis of CD20 positive
cells.
b. The treatment of the disease using the drug Imiquimod, which activates
the innate immune system through TLR-7 and can lead to the activation
of B-cells through cell migration to the lymph nodes.
c. Removal of the spleen to eliminate a large portion of potential
autoerythrocyte antibody producing B-cells
d. Gene therapy that utilizes suppressive genes to downregulate the
production of anti-erythrocyte auto-antibodies
Study Questions
4. Which type of AIHA is the most common?
a. Cold
b. Mixed
c. Warm
d. Drug Induced
10
11/24/2014
Study Questions
5. Which of the following statements about AIHA is
false?
a. Mixed AIHA involves the formation of hapten molecules that
activate an immune response.
b. The onset of symptoms of AIHA is typically slow, but can
include dizziness, jaundice, and rapid heart beat.
c. There is no race or gender component, no age pre-
selection, and no identified genetic background for AIHA.
d. The most common test for AIHA is the direct antiglobulin test
(DAT), which utilizes anti-human globulins to detect the
presence of antibody coated RBCs via agglutination.
Answers
1. Autoimmune Hemolytic Anemia is the increased destruction of
erythrocytes due to the presence of anti-erythrocyte
autoantibodies (AEA).
1. Binding of self AB (Polyclonal) to Rh proteins, causing Fc
receptors to mediate removal of RBCs within the spleen
2. Imbalances in IL-10 and IL-12 believed to play a role
2. C
3. B
4. C
5. A
11
11/24/2014
References
Bass BF, Tuscano ET, Tuscano JM. 2014. Diagnosis and classification of autoimmune hemolytic
anemia. Autoimmunity Reviews, 13: 560-564.
Hastings CA, Torkildson JC, Agrawal AK. 2012. Hemolytic anemia. Handbook of Pediatric Hematology and
Oncology: Childrens Hospital & Research Center Oakland, Second Edition. 10-17.
Lambert J, Nydegger UE. 2010. Geoepidemiology of autoimmune diseases. Autoimmunity Reviews 9: 350-354.
Liu B, Gu W. 2013. Immunotherapy treatments of warm autoimmune hemolytic anemia. Clinical and developmental
Immunology. 1-6.
Olsson M, Hagnerud S, Hedelius DUR, Oldenborg P. 2006. Hematologic diseases: Autoimmune hemolytic anemia
and immune thrombocytopenic purpura. Immunogenetics of Autoimmune Disease. 135-143.
Petz L. Cold antibody autoimmune hemolytic anemias. Blood reviews. 2008. 22. 1-15.
Stahl D, Sibrowski W. Warm autoimmune hemolytic anemia is an IgM-IgG immune complex disease. Journal of
Autoimmunity. 2005. 25. 272-282.
12